What is SwipeRx?
SwipeRx operates as a pivotal digital platform within the pharmaceutical supply chain, bridging the gap between manufacturers and local pharmacies. By digitizing procurement and inventory management, the company addresses critical inefficiencies in the distribution of essential medicines. With a workforce of 100 to 249 employees, SwipeRx has established itself as a key player in the regional health-tech ecosystem, leveraging technology to enhance access to healthcare products. Its market position is defined by its ability to integrate fragmented pharmacy networks into a cohesive, data-driven digital marketplace, thereby driving transparency and operational excellence across the industry.
How much funding has SwipeRx raised?
SwipeRx has raised a total of $33.3M across 2 funding rounds:
Series A
$6.3M
Series B
$27M
Series A (2017): $6.3M with participation from Kickstart Ventures, IMJ Investment Partners, MDI Ventures, Unitus Impact, 500 Global, Endeavor, and Global Innovation Fund
Series B (2022): $27M led by Susquehanna International Group, Bill & Melinda Gates Foundation, MDI Ventures, and Johnson & Johnson Impact Ventures
Key Investors in SwipeRx
Susquehanna International Group
A privately held global financial firm that leverages quantitative applications to provide liquidity and execution services, with a robust portfolio in venture capital and private equity.
Bill & Melinda Gates Foundation
A major philanthropic organization focused on global health and development, investing in innovative solutions to improve lives and reduce extreme poverty.
MDI Ventures
A global multi-stage venture capital firm that drives digital transformation and innovation by supporting technology-driven startups in Southeast Asia.
What's next for SwipeRx?
With the recent influx of capital, SwipeRx is well-positioned to accelerate its regional expansion and deepen its technological capabilities. The company is expected to focus on enhancing its supply chain analytics and expanding its footprint in emerging markets where pharmaceutical access remains a challenge. By leveraging the expertise of its diverse investor base, SwipeRx will likely prioritize the development of new digital services that support pharmacy digitization and improve patient outcomes. As the firm transitions into its next phase of growth, the focus will remain on scaling its enterprise-level solutions to meet the increasing demand for reliable, tech-enabled pharmaceutical distribution networks.
See full SwipeRx company page
